NCT03753919 2026-03-11
DUTHY
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Terminated
Clinical Trials
46 trialsNCT03211988 2026-03-02
Entinostat Neuroendocrine (NE) Tumor
Columbia University
Phase 2 Terminated
NCT03165721 2026-02-18
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT05987176 2026-01-14
NELMAS
Imperial College London
Phase 2 Terminated
NCT04042714 2025-11-04
TAS-102 NEC
Baylor Research Institute
Phase 2 Terminated
NCT04985604 2025-10-02
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
Phase 2 Terminated
NCT05420636 2025-07-30
Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET
Fox Chase Cancer Center
Phase 2 Terminated
NCT04579679 2025-07-25
Open-Label Surufatinib in European Patients With NET
Hutchmed
Phase 2 Terminated
NCT05634577 2025-06-19
A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT07012330 2025-06-10
Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients
Erasmus Medical Center
Phase 2 Terminated
NCT03387592 2025-03-10
SENECA
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Terminated
NCT04538378 2025-01-27
Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02489604 2025-01-13
LUNET
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Terminated
NCT02736448 2025-01-13
Lu-Ca-S
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Terminated
NCT03420521 2024-01-09
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT02859064 2023-12-05
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT02031536 2023-06-29
Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT03630120 2021-07-14
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT03190213 2021-06-22
Pembro NEC
University of Utah
Phase 2 Terminated
NCT03670030 2021-06-10
A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System
Ochsner Health System
Phase 2 Terminated
NCT02749227 2021-04-27
PASSILCORT
Columbia University
Phase 2 Terminated
NCT01915303 2020-09-18
Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
Novartis
Phase 2 Terminated
NCT02315625 2020-09-09
Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00616642 2020-08-14
Rosiglitazone in Treating Patients With Pituitary Tumors
Jonsson Comprehensive Cancer Center
Phase 2 Terminated
NCT00985946 2019-12-09
Study of Panobinostat in Patients With Neuroendocrine Tumors
University of Wisconsin, Madison
Phase 2 Terminated
NCT02657369 2019-10-15
A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
Eisai Inc.
Phase 2 Terminated
NCT01966809 2019-08-20
Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas
Medical College of Wisconsin
Phase 2 Terminated
NCT01994213 2019-01-22
A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Terminated
NCT03002623 2018-12-21
CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02001051 2018-06-14
Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00126568 2018-01-19
Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01056601 2017-12-28
Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT01340794 2017-09-21
Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01719861 2017-04-17
Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors
Stanford University
Phase 2 Terminated
NCT00947167 2017-03-03
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Stanford University
Phase 2 Terminated
NCT01374451 2016-12-20
COOPERATE-2
Novartis
Phase 2 Terminated
NCT00958841 2016-07-26
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
Novartis
Phase 2 Terminated
NCT01628913 2016-04-07
Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors
Novartis
Phase 2 Terminated
NCT01215578 2015-04-30
NET
Assistance Publique - Hôpitaux de Paris
Phase 2 Terminated
NCT01886287 2015-01-12
P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00778817 2014-04-29
IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00115739 2014-04-21
Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT00095693 2014-01-16
Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00084461 2013-06-04
Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00002921 2012-10-05
S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery
SWOG Cancer Research Network
Phase 2 Terminated
NCT00466856 2012-05-18
Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated